Put Option Activity Highlights
On 18 March 2026, Sun Pharma’s put options with a strike price of ₹1800 witnessed a robust trading volume of 2,151 contracts, generating a turnover of approximately ₹15.5 crores. The open interest stands at 1,951 contracts, indicating sustained interest in downside protection or speculative bearish bets. The underlying stock closed at ₹1797.4, just 2.98% shy of its 52-week high of ₹1851.2, underscoring the significance of this strike price as a psychological and technical level for traders.
The expiry date of 30 March 2026 is less than two weeks away, which often leads to heightened option activity as traders adjust their positions or hedge existing exposures. The concentration of put option trades at ₹1800 suggests that investors are either anticipating a potential pullback from current levels or seeking to protect gains amid recent volatility.
Stock Price and Technical Context
Sun Pharma’s stock has been on a modest upward trajectory, gaining 0.81% over the past two trading sessions. However, it marginally underperformed its sector by 0.4% on the day, closing with a 0.18% gain compared to the Pharmaceuticals & Biotechnology sector’s 0.58% rise and the Sensex’s 0.56% advance. The stock’s trading range remains narrow, confined to ₹12.8 on the day, reflecting a cautious market stance.
Technically, the stock is trading above its 20-day, 50-day, 100-day, and 200-day moving averages, signalling a generally bullish medium- to long-term trend. However, it remains below its 5-day moving average, indicating some short-term consolidation or profit-taking. Delivery volumes have declined by over 20% compared to the five-day average, suggesting reduced investor participation despite the stock’s liquidity, which comfortably supports trade sizes of up to ₹9.04 crores based on recent volumes.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Investor Sentiment and Hedging Implications
The surge in put option activity at the ₹1800 strike price, close to the current market price, suggests a cautious or bearish sentiment among traders. Put options serve as insurance against price declines, and the elevated open interest indicates that many investors are either hedging existing long positions or speculating on a near-term correction.
Given Sun Pharma’s large-cap status with a market capitalisation of ₹4,31,304.45 crores and a Mojo Score of 72.0, upgraded from a previous Hold to a Buy rating on 23 February 2026, the stock remains fundamentally strong. However, the option market activity reveals that some market participants are wary of potential volatility or sector-specific headwinds in the Pharmaceuticals & Biotechnology space.
It is also notable that the stock’s recent underperformance relative to its sector and the Sensex, albeit marginal, may be contributing to the cautious positioning. The pharmaceutical sector often faces regulatory and pricing pressures, which can prompt investors to seek downside protection through puts.
Expiry Patterns and Market Dynamics
As the 30 March expiry approaches, option writers and buyers typically adjust their positions to manage risk and capitalise on expected price movements. The concentration of put contracts at ₹1800 could act as a support level, with traders expecting the stock to hold above this price or to limit losses if it dips below.
Open interest data suggests that the ₹1800 strike is a focal point for market participants, with nearly 2,000 contracts outstanding. This level may attract increased attention in the coming days, potentially influencing price action as expiry nears.
Investors should monitor the interplay between the stock’s price movements and option market activity closely, as shifts in open interest and volume can provide early signals of changing market sentiment or impending volatility.
Sun Pharmaceutical Industries Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this large-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth large-cap analysis
- - Valuation assessment included
Outlook for Investors
For investors holding Sun Pharma shares, the current option market activity underscores the importance of vigilance in the near term. While the stock’s fundamentals remain robust and the Mojo Grade upgrade to Buy reflects positive medium-term prospects, the elevated put option volumes suggest that downside risks are being actively managed.
Traders may consider the ₹1800 level as a critical support zone, with the option expiry potentially acting as a catalyst for price consolidation or volatility. Those looking to initiate new positions should weigh the technical signals alongside the broader sector outlook and regulatory environment.
In summary, the heavy put option trading in Sun Pharma ahead of the March expiry highlights a nuanced market stance: confidence in the stock’s long-term value tempered by caution over short-term fluctuations. This dynamic is typical in large-cap pharmaceutical stocks where sector-specific risks coexist with steady growth potential.
Summary
Sun Pharmaceutical Industries Ltd’s put options at the ₹1800 strike price have attracted significant trading interest, with over 2,100 contracts exchanged and open interest nearing 2,000 contracts ahead of the 30 March 2026 expiry. The stock’s proximity to its 52-week high, combined with recent technical signals and sector performance, has prompted investors to hedge or speculate on potential downside. Despite a recent Mojo Grade upgrade to Buy and strong fundamentals, the option market activity suggests a cautious near-term outlook, making the ₹1800 strike a key level to watch for price support and volatility cues.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
